Genmab A/S Genmab Announces Appointment Of Martine Van Vugt To Chief Strategy Officer
28 March 2023 - 5:00PM
UK Regulatory
TIDMGEN
Media Release
COPENHAGEN, Denmark; March 28, 2023
https://www.globenewswire.com/Tracker?data=Bak0jj6DOWp589F2s22SlaGZUY8AdcoRUyYTq_oj3cwORqxc_HFZlib_sbfV6Tr23o5-8n7_7d4z5zxDxjrlvg==
Genmab A/S (Nasdaq: GMAB) announced today that Martine van Vugt has
been appointed to Chief Strategy Officer and promoted to Executive
Vice President effective March 29, 2023. Martine will oversee
Corporate Strategy, Corporate Development, Business Development and
Licensing and Alliance Management. Martine joined Genmab in 2001
and most recently served as Genmab's Senior Vice President,
Corporate Strategy & Planning. She will continue her role as a
member of the Executive Committee with Genmab's President and Chief
Executive Officer Dr. Jan van de Winkel, Chief Development Officer
Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, Chief
Medical Officer Dr. Tahi Ahmadi, Chief Operating Officer Anthony
Mancini, Chief Legal Officer Birgitte Stephensen, and Chief People
Officer Chris Cozic.
Based in Genmab's Global R&D Center in Utrecht, the
Netherlands, Martine began her career in scientific and research
positions and gained increased responsibility through her time at
Genmab leading to extensive experience as participant in many of
Genmab's governance fora. She is a critical contributor to multiple
business development strategic collaborations and has been
instrumental in the structure and negotiations of key partnerships,
among them Genmab's collaborations with Janssen, BioNTech, and
AbbVie.
"Genmab is on an exciting and pivotal journey as we deliver on
our promise to bring truly innovative antibody medicines to
patients. Martine's skilled approach to corporate strategy and
business development has contributed to productive relationships
with our partners and to the successful management of our
alliances," said Jan van de Winkel, Ph.D., Chief Executive Officer
of Genmab. "I'm delighted to recognize Martine for her strong
contributions to Genmab."
Martine has a Ph.D. in Immunology from Utrecht University and a
Master of Science degree in Biology from Wageningen University.
About Genmab
Genmab is an international biotechnology company with a core
purpose guiding its unstoppable team to strive towards improving
the lives of patients through innovative and differentiated
antibody therapeutics. For more than 20 years, its passionate,
innovative and collaborative team has invented next-generation
antibody technology platforms and leveraged translational research
and data sciences, which has resulted in a proprietary pipeline
including bispecific T-cell engagers, next-generation immune
checkpoint modulators, effector function enhanced antibodies and
antibody-drug conjugates. To help develop and deliver novel
antibody therapies to patients, Genmab has formed 20+ strategic
partnerships with biotechnology and pharmaceutical companies. By
2030, Genmab's vision is to transform the lives of people with
cancer and other serious diseases with Knock-Your-Socks-Off (KYSO)
antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
Genmab.com
https://www.globenewswire.com/Tracker?data=Bak0jj6DOWp589F2s22SlYXoKbeMyFj_dZr_4dpsfQSlJkKmrNyOunWlEwh8ckWOfW84Fhi344jItLjwwsjNXQ==
and follow us on Twitter.com/Genmab
https://www.globenewswire.com/Tracker?data=0t1mWxfttB-VWrgewjBblFQHNVVAG4GdkZ8tpGdancxsHn7IoDbxQ-JUbJ18TPkb3rGK2vyzlEx1tt7DJX_3GGpTOT0FiJZeXoGue96fOyQ=
.
Contact:
Marisol Peron, Senior Vice President, Global Communications
& Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=i8JZqNIMCGkaSX0yZek4IXq1iF82zxxS0xt1jYWfuuwGApu2sqtIxugZgl348SZilxsZWgQnUaKWK_HVYfXR7g==
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=dQfVhkx9Rqv_npHFf1QZWkRAo1ED0uXLCOQ0BYzGUf3gHXFAsHSj_yQ7FThcXX6wRKOq2dZUgjVvt1WnV2gtxQ==
This Media Release contains forward looking statements. The
words "believe", "expect", "anticipate", "intend" and "plan" and
similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=ExsV_pizRrI2HxMToYMGID6D15yNvcT0T3f9MZgBk0-4OQE2YYRoMk9ivdR7g9nfRS37HpX6-hRh7DTQ9K7Vrw==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=ExsV_pizRrI2HxMToYMGIDjhb9MMZjKCSvUx1UAwfl5MQ0Y34D792YFFYOe3Lppp2ms9cvfRsA0v8KvjOB_BR6C4KyVyCF7mSFSsbwm0eng=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Media Release nor to
confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Media Release no. 03
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 280323_i03_EVP_CSO
https://ml-eu.globenewswire.com/Resource/Download/ebb8ccbd-54b5-4775-8770-3bf91a702736
(END) Dow Jones Newswires
March 28, 2023 02:00 ET (06:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024